Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.67, $0.05 better than the analyst estimate of $0.62. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.49 billion.

GUIDANCE:

Edwards Lifesciences sees FY2025 EPS of $2.40-$2.50, versus the consensus of $2.47.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.